 |
CASI Pharmaceuticals, Inc. 9620 Medical Center Drive Suite 300 Rockville, MD 20850 Office (240) 864-2600 Fax (301) 315-2437 NASDAQ: CASI |
November 30, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Mail Stop 4546
Attn: Laura Crotty
| Re: | CASI Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-250801 Request for Acceleration |
Ladies and Gentlemen:
CASI Pharmaceuticals, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission accelerate the effective date of its Registration Statement on Form S-3 (File No. 333-250801), so that it may become effective at 4:00 p.m. Eastern Time on December 2, 2020, or as soon thereafter as practicable.
Very truly yours,
CASI PHARMACEUTICALS, INC. | |
By: /s/ Cynthia W. Hu Name: Cynthia W. Hu Title: COO, General Counsel and Secretary |